- C-H Alkylation of Aldehydes by Merging TBADT Hydrogen Atom Transfer with Nickel Catalysis
-
Catalyst controlled site-selective C-H functionalization is a challenging but powerful tool in organic synthesis. Polarity-matched and sterically controlled hydrogen atom transfer (HAT) provides an excellent opportunity for site-selective functionalization. As such, the dual Ni/photoredox system was successfully employed to generate acyl radicals from aldehydes via selective formyl C-H activation and subsequently cross-coupled to generate ketones, a ubiquitous structural motif present in the vast majority of natural and bioactive molecules. However, only a handful of examples that are constrained to the use of aryl halides are developed. Given the wide availability of amines, we developed a cross-coupling reaction via C-N bond cleavage using the economic nickel and TBADT catalyst for the first time. A range of alkyl and aryl aldehydes were cross-coupled with benzylic and allylic pyridinium salts to afford ketones with a broad spectrum of functional group tolerance. High regioselectivity toward formyl C-H bonds even in the presence of α-methylene carbonyl or α-amino/oxy methylene was obtained.
- Murugesan, Vetrivelan,Ganguly, Anirban,Karthika, Ardra,Rasappan, Ramesh
-
supporting information
p. 5389 - 5393
(2021/07/21)
-
- A pH-Switchable Aqueous Organocatalysis with Amphiphilic Secondary Amine–Porphyrin Hybrids
-
A series of amphiphilic 5-(cyclic-secondary-amine)-10,15,20-tris(4-sulfonatophenyl)porphyrins, designed with the aim of using the amphiphilic porphyrin moiety for the modulation of the aggregation state of the compound by the pH of the medium, have been synthesised, and the relationship between their supramolecular behaviour in acidic aqueous media and their organocatalytic activity in Michael and aldol reactions has been investigated. In particular, we have found that the catalytic activity of the pyrrolidine moiety in an amphiphilic isoindoline–porphyrin hybrid for the aldol reaction of cyclohexanone with 4-nitrobenzaldehyde can be selectively and reversibly switched on and off by adjusting the homogeneity of its solutions through pH variations. The catalysis of the aldol reaction by the secondary amine moiety would otherwise take place regardless of the pH of the medium. We have demonstrated that the aggregation behaviour of these amine–porphyrin hybrids can be also used for the recovery and reutilization of the catalysts.
- Arlegui, Aitor,Crusats, Joaquim,Cuesta, Victor,Moyano, Albert,Torres, Pol
-
supporting information
(2020/07/08)
-
- Can Heteroarenes/Arenes Be Hydrogenated Over Catalytic Pd/C Under Ambient Conditions?
-
Hydrogenation of over a dozen aromatic compounds, including both heteroarenes and arenes, over palladium on carbon (Pd/C, 1–100 molpercent) with H2-balloon pressure at room temperature is reported. Analyses using pyridine as a model substrate revealed that acetic acid was the best solvent, as using only 1 molpercent Pd/C provided piperidine quantitatively. Substrate scope analysis and density functional theory calculations indicated that reaction rates are highly dependent on frontier molecular orbital characteristics and the steric bulkiness of substituents. Moreover, the established method was used for the concise synthesis of the anti-Alzheimer drug donepezil (Aricept?).
- Tanaka, Nao,Usuki, Toyonobu
-
p. 5514 - 5522
(2020/07/24)
-
- QUINAZOLINONES AS PARP14 INHIBITORS
-
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
- -
-
Paragraph 0298; 0311; 0312
(2019/07/10)
-
- Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase
-
Pleiotropic intervention may be a requirement for effective limitation of the progression of multifactorial diseases such as Alzheimer's Disease. One approach to such intervention is to design a single chemical entity capable of acting on two or more targets of interest, which are accordingly known as Multi-Target Directed Ligands (MTDLs). We recently described donecopride, the first MTDL able to simultaneously inhibit acetylcholinesterase and act as an agonist of the 5-HT4 receptor, which displays promising activities in vivo. Pharmacomodulation of donecopride allowed us to develop a novel series of indole derivatives possessing interesting in vitro activities toward AChE and the σ1 receptor. The crystal structures of complexes of the most promising compounds with Torpedo californica AChE were solved in order to further understand their mode of inhibition.
- Lalut, Julien,Santoni, Gianluca,Karila, Delphine,Lecoutey, Cédric,Davis, Audrey,Nachon, Florian,Silman, Israel,Sussman, Joel,Weik, Martin,Maurice, Tangui,Dallemagne, Patrick,Rochais, Christophe
-
supporting information
p. 234 - 248
(2018/11/24)
-
- Novel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease
-
Facing the complexity of Alzheimer's disease (AD), it is now currently admitted that a therapeutic pleiotropic intervention is needed to alter its progression. Among the major hallmarks of the disease, the amyloid pathology and the oxidative stress are closely related. We propose in this study to develop original Multi-Target Directed Ligands (MTDL) able to impact at the same time Aβ protein accumulation and toxicity of Reactive Oxygen Species (ROS) in neuronal cells. Such MTDL were obtained by linking on a central piperidine two scaffolds of interest: a typical aminochlorobenzophenone present in numerous 5-HT4R agonists, and diverse antioxidant chemotypes. Interestingly, the most active compound 9g possesses a Ki of 12.7 nM towards 5-HT4R and an antioxidant activity in vitro and in cellulo.
- Lanthier, Caroline,Payan, Hugo,Liparulo,Hatat, Bérénice,Lecoutey, Cédric,Since, Marc,Davis, Audrey,Bergamini, Christian,Claeysen, Sylvie,Dallemagne, Patrick,Bolognesi, Maria-Laura,Rochais, Christophe
-
-
- INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)
-
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
- -
-
Paragraph 525
(2018/02/28)
-
- From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease
-
The lack of an effective treatment for Alzheimer’ disease (AD), an increasing prevalence and severe neurodegenerative pathology, boost medicinal chemists to look for new drugs. Currently, only acethylcholinesterase (AChE) inhibitors and glutamate antagonist have been approved to the palliative treatment of AD. Although they have a short-term symptomatic benefits, their clinical use have revealed important non-cholinergic functions for AChE such its chaperone role in beta-amyloid toxicity. We propose here the design, synthesis and evaluation of non-toxic dual binding site AChEIs by hybridization of indanone and quinoline heterocyclic scaffolds. Unexpectely, we have found a potent allosteric modulator of AChE able to target cholinergic and non-cholinergic functions by fixing a specific AChE conformation, confirmed by STD-NMR and molecular modeling studies. Furthermore the promising biological data obtained on human neuroblastoma SH-SY5Y cell assays for the new allosteric hybrid 14, led us to propose it as a valuable pharmacological tool for the study of non-cholinergic functions of AChE, and as a new important lead for novel disease modifying agents against AD.
- Chierrito, Talita P.C.,Mantoani, Susimaire P.,Roca, Carlos,Requena, Carlos,Sebastian-Perez, Victor,Castillo, Willian O.,Moreira, Natalia C.S.,Pérez, Concepción,Sakamoto-Hojo, Elza T.,Takahashi, Catarina S.,Jiménez-Barbero, Jesús,Ca?ada, F. Javier,Campillo, Nuria E.,Martinez, Ana,Carvalho, Ivone
-
p. 773 - 791
(2017/09/02)
-
- Synthesis and in vitro evaluation of donepezil-based reactivators and analogues for nerve agent-inhibited human acetylcholinesterase
-
Poisoning by organophosphorus nerve agents and pesticides is a serious public and military health issue with over 200 000 fatalities annually worldwide. Conventional emergency treatment consists of rapid administration of atropine and pyridinium oxime as an antidote. The reactivation of acetylcholinesterase (AChE) in the central nervous system (CNS) by the oxime is inefficient due to the fact that positively charged pyridiniums do not readily cross the blood brain barrier (BBB). Herein, we described the synthesis and in vitro evaluation of four donepezil-based non quaternary reactivators. The compounds 1-4 have been prepared in 7-8 linear steps in 1-9% overall yields and oximes 1-3 show better ability (8 fold higher) than pralidoxime to reactivate VX-inhibited human AChE (VX-hAChE). Besides, oxime 2 is 5 to 11 fold more efficient than pralidoxime and HI-6 respectively for the reactivation of VX-inhibited human butyrylcholinesterase (VX-hBChE).
- Renou, Julien,Dias, José,Mercey, Guillaume,Verdelet, Tristan,Rousseau, Catherine,Gastellier, Anne-Julie,Arboléas, Mélanie,Touvrey-Loiodice, Mélanie,Baati, Rachid,Jean, Ludovic,Nachon, Florian,Renard, Pierre-Yves
-
p. 17929 - 17940
(2016/03/01)
-
- A facile synthesis of the spiroindoline-based growth hormone secretagogue, MK-677
-
A facile and improved route for the synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 was described. The key step adopted the Fischer indole/reduction strategy. The preparation of the key intermediates N-protected piperidine carboxaldehyde 5 and the N-Boc-O-benzyl-d-serine (2) are also optimized.
- Qi, Xian Liang,Yang, Er Qun,Zhang, Jun Tao,Wang, Tao,Cao, Xiao Ping
-
scheme or table
p. 661 - 664
(2012/07/03)
-
- COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT
-
Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.
- -
-
Page/Page column 27
(2010/04/03)
-
- Novel antagonists of serotonin-4 receptors: Synthesis and biological evaluation of pyrrolothienopyrazines
-
Based on the definition of a 5-HT4 receptor antagonist pharmacophore, a series of pyrrolo[1,2-a]thieno[3,2-e] and pyrrolo[1,2-a]thieno[2,3-e] pyrazine derivatives were designed, prepared, and evaluated to determine the properties necessary for high-affinity binding to 5-HT4 receptors. The compounds were synthesized by substituting the chlorine atom of the pyrazine ring with various N-alkyl-4-piperidinylmethanolates. They were evaluated in binding assays with [3H]GR113808 (1) as the 5-HT4 receptor radioligand. The affinity values (Ki or inhibition percentages) were affected by both the substituent on the aromatic ring and the substituent on the lateral piperidine chain. A methyl group on the tricyclic ring produced a marked increase in affinity while an N-propyl or N-butyl group gave compounds with nanomolar affinities. Among the most potent ligands, 34d was selected for further pharmacological studies and evaluated in vivo. This compound acts as an antagonist/weak partial agonist in COS-7 cells stably expressing the 5-HT4(a) receptor and is of great interest as a peripheral antinociceptive agent.
- Lemaitre, Stephane,Lepailleur, Alban,Bureau, Ronan,Butt-Gueulle, Sabrina,Lelong-Boulouard, Veronique,Duchatelle, Pascal,Boulouard, Michel,Dumuis, Aline,Daveu, Cyril,Lezoualc'h, Frank,Pfeiffer, Bruno,Dauphin, Francois,Rault, Sylvain
-
scheme or table
p. 2607 - 2622
(2009/09/06)
-
- Synthesis of α,α-difluoro-β-amino esters or gem-difluoro-β-lactams as potential metallocarboxypeptidase inhibitors
-
The synthesis of gem-difluorinated β-lactams and gem-difluorinated β-amino acids, each possessing a potential basic functional group, from ethyl bromodifluoroacetate and either imines (for β-lactams) or N-(α-aminoalkyl)benzotriazoles (for β-amino esters) was investigated. A series of these compounds were used for the design of novel metallocarboxypeptidase inhibitors. N-Alkylation and N-acylation of these two versatile scaffolds were carried out, leading to the expected targets in moderate to good yields. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
- Boyer, Nicolas,Gloanec, Philippe,De Nanteuil, Guillaume,Jubault, Philippe,Quirion, Jean-Charles
-
experimental part
p. 4277 - 4295
(2009/04/10)
-
- PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS
-
Pyrrolopyrimidine derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.
- -
-
Page/Page column 68-69
(2008/12/04)
-
- Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
-
This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
- -
-
-
- PYRAZOLOPYRIDINE DERIVATES
-
New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.
- -
-
-
- Nitric oxide donors, compositions and methods of use related applications
-
The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.
- -
-
-
- SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS
-
The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed
- -
-
-
- Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
-
Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis
- -
-
-
- Benzothiazole derivatives with activity as adenosine receptor ligands
-
The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.
- -
-
-
- 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity
-
The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
- -
-
-
- 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
-
The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4fare defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
- -
-
-
- Cyanoguanidine compounds
-
A cyanoguanidine compound of the following formula: is disclosed. A cyanoguanidine compound of the present invention possess a high specificity for tumor cells. Also disclosed are methods for preparing a cyanoguanidine compound.
- -
-
-
- AROMATIC COMPOUNDS HAVING CYCLIC AMINO OR SALTS THEREOF
-
Compounds represented by general formula (I) or salts thereof which specifically inhibit FXa, exert a potent anticoagulant effect and thus are useful as medicinal compositions, wherein G1 to G4, X and Y represent each CH or N; Z1 represents -SO2- or -CH2 -; Q represents aryl or heteroaryl; and R1 to R9 represent each hydrogen or a substituent.
- -
-
-
- Azetidine, pyrrolidine and piperidine derivatives
-
A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.
- -
-
-
- Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof
-
Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.
- -
-
-
- The SAR of UK-78,282: A novel blocker of human T cell Kv1.3 potassium channels
-
UK-78,282 was identified in a human T cell 86Rb efflux high-throughput screen of our compound libraries. This compound was found to be a potent and selective blocker of human T cell voltage-gated K+ channels and to inhibit T cell activation. The SAR around UK-78,282 and a general pharmacophore hypothesis are presented in this communication.
- Burgess, Laurence E.,Koch, Kevin,Cooper, Kelvin,Biggers, Michael S.,Ramchandani, Mukesh,Smitrovich, Jacqueline H.,Gilbert, Eric J.,Bruns, Matthew J.,Mather, Robert J.,Donovan, Carol B.,Hanson, Douglas C.
-
p. 1047 - 1052
(2007/10/03)
-
- Methanoanthrancenyl piperidyl antipsychotics
-
Compounds of formula I STR1 wherein X and Y are H or halo; R 2 is: [structures Ia, Ib or Ic;] STR2 R 3 is selected from unsubstituted or substituted alkyl, aryl or heteroaryl groups;R 4 is selected from H or (Cl-6)alkyl,and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disoders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropschiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
- -
-
-
- Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
-
Compounds of the formula STR1 wherein R1 is selected from STR2 Y is a bond or lower alkylene; R2 and R3 are independently hydrogen, lower-alkyl or halogen; R4 is STR3 R5 is hydrogen, lower-alkyl or halogen; R6 is hydrogen, lower-alkyl or halogen; R7 is hydrogen or lower-alkyl; R8 is hydrogen, lower-alkyl, or trifluoromethyl; R9 is lower-alkyl; R10 is lower-alkyl, trifluoromethyl or difluoromethyl; or pharmaceutically acceptable acid addition salts thereof are useful as antiviral agents.
- -
-
-
- 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES AND THEIR APPLICATION IN THERAPY
-
A benzazepine derivative which is a compound of formula (I): STR1 in which each of m and n denotes the number 1, oreach of m and n denotes the number 2, orm denotes the number 3 and n denotes the number 1; and R denotes hydrogen or a group of formula--Z--R' in which Z denotes a--CO--or--CH 2--group and R' denotes a phenyl group which is unsubtituted or substituted with from one to three substituents selected from halogen atoms, linear or branch (C. sub.1-C 3) alkyl groups and linear or branched (C 1-C 3) alkoxy groups, or a pharmacologically acceptable acid addition salt.
- -
-
-
- Muscarinic Receptor Binding and Activation of Second Messengers by Substituted N-Methyl-N-acetamides
-
A series of substituted azacycloalkyl analogues of the muscarinic agonist UH 5 (N-methyl-N-acetamide, 1a) were synthesized and evaluated pharmacologically.These compounds were developed as intermediates for further derivatization leading to functionalized congeners of 1a.The compounds were synthesized by using a Mannich-type condensation of N-acetyl-N-methylpropargylamine to various substituted saturated azaheterocycles.The compounds were screened at a single concentration in competitive binding assays in rat cerebral cortical membranes against either N-methylscopolamine (at 100 μM) or oxotremorine-M (at 1 μM) labels.Candidates were then selected for further evaluation of their effect on phosphoinositide (PI) turnover in membranes from A9L cells transfected with cDNA of either m1-muscarinic cholinergic receptors (m1AChRs) or m3AChRs.The analogues were also tested for the inhibition of adenylate cyclase in NG108-15 cells expressing m4AChRs.The azetidine analogue of 1a had a Ki value of 12 nM for the inhibition of oxotremorine-M binding in rat brain and had an agonist potency at m1-, m3-, and m4AChRs comparable to 1a.The substituted 5- and 6-member ring analogues generally had lower binding affinities and were less potent than 1a in stimulating PI turnover.Several compounds were moderately effective in inhibiting cyclic AMP production in NG108-15 cells.
- Bradbury, Barton J.,Baumgold, Jesse,Paek, Robert,Kammula, Udai,Zimmet, Jeff,Jacobson, Kenneth A.
-
p. 1073 - 1079
(2007/10/02)
-
- DERIVATIVES OF 2-((4-PIPERIDINYL)METHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
-
A compound of formula (I): STR1 in which: X is hydrogen or a methyl or methoxy group;Y is a halogen or a methyl or methoxy group; andR is a group of formula--Z--R' in which:Z is a--CH 2--group, and R' is a phenyl group unsubstituted or substituted by one, two or three substituents selected from halogen atoms and trifluoromethyl, linear or branched (C. sub.1-C 3) alkyl and linear or branched (C 1-C 3) alkoxy groups;or a pharmacologically acceptable acid addition salt thereof.
- -
-
-
- 2-((4-piperidyl)methyl)benzofuro(2,3-C)pyridine derivatives, and their application in therapy
-
A compound of formula (I) STR1 in which R is a benzyl, benzoyl, 3-chlorobenzoyl, 3-methylbenzoyl or (C1 -C6 alkoxy)carbonyl group, or a pharmacologically acceptable acid addition salt thereof.
- -
-
-
- 2-[(4-PIPERIDYL)METHYL]-1,2,3,4-TETRAHYDRO-9H-PYRIDO[3,4-B]INDOLE DERIVATIVES, AND THEIR APPLICATION IN TREATING DEPRESSIVE STATE, ANXIETY STATE OR HYPERTENSION
-
A compound which is a pyrido[3,4-b]derivative of formula (I) STR1 in which R is a hydrogen atom or an alkyl carbonyl, arylalkylcarbonyl or arylcarbonyl group of formula COR 1 wherein R. sub.1 is a C 1-C. sub.6 alkyl group, a benzyl group or a phenyl group unsubstituted or substituted with 1 to 3 substituents chosen from halogen atoms and trifluoromethyl, C 1-C 3 alkyl and C 1-C. sub.3 alkoxy groups or R is an alkoxycarbonyl or benzyloxycarbonyl group of formula COOR 2 wherein R 2 is a C 1-C 6 alkyl group or a benzyl group, or R is a substituted aminocarbonyl group of formula CONHR 3 wherein R 3 is a C 1-C 6 alkyl group or a phenyl group, or R is an arylsulphonyl group of formula SO 2 R. sub.4 wherein R 4 is a phenyl group, or a pharmacologically acceptable acid addition salt thereof useful for treating hypertension, depressive state or anxiety state.
- -
-
-
- 2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy
-
A compound of formula (I) STR1 in which R is (a) a hydrogen atom; (b) a linear or branched (C1 -C6) alkyl group; an allyl group; a cycloalkylmethyl group in which the cycloalkyl moiety has from 3 to 6 carbon atoms; a phenylmethyl group unsubstituted or substituted with one to three substituents chosen from halogen atoms and trifluoromethyl, nitro, amino, dimethylamino, cyano, aminocarbonyl, linear or branched (C1 -C3) alkyl, linear or branched (C1 -C3) alkoxy and linear or branched (C1 -C3) alkylthio groups; a 2-phenylethyl group; a 3-phenylpropyl group; a 3-phenyl-2-propenyl group; a phenylcarbonylmethyl group; a naphthylmethyl group; a pyridylmethyl group; a furylmethyl group; or a thienylmethyl group; or (c) a linear or branched (C2 -C6) alkanoyl group; a cycloalkylcarbonyl group in which the cycloalkyl moiety has from 3 to 6 carbon atoms; a trifluoroacetyl group; a phenyl-carbonyl group unsubstituted or substituted with one to three substituents chosen from halogen atoms and trifluoromethyl, nitro, linear or branched (C1 -C3) alkyl, linear or branched (C1 -C3) alkoxy and linear or branched (C1 -C3) alkylthio groups; a 1-oxo-3-phenyl-2-propenyl group; a naphthylcarbonyl group; a pyridylcarbonyl group; a furylcarbonyl group; a thienylcarbonyl group; a (2-indolyl)-carbonyl group; or a (5-indolyl)carbonyl group; or a pharmacologically acceptable acid addition salt thereof.
- -
-
-
- Diphenylmethylene piperidines
-
Novel chemical compounds which are diphenylmethylene piperidine compounds are provided, as well as methods for their production, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds in dosage form. The compounds have both anticholinergic and antidopaminergic properties, and are useful as antiemetic, antihistamine, pulmonary, antiallergy, and antispasmodic agents.
- -
-
-
- 4-Phenoxymethyl-piperidines
-
4-Phenoxymethyl-piperidines of the formula STR1 wherein R is hydrogen, halogen, nitro, lower alkyl or lower alkoxy, in the form of the free base or an acid addition salt, are provided and they are useful as intermediates in the production of anti-hypertensive agents through condensation with (a) propyl chloride and then with an adenine, or (b) a propyl indole.
- -
-
-
- 3,6-Bis-(heterocyclic aminoacyl-amino)-acridines and salts thereof
-
Compounds of the formula STR1 wherein R1 is hydrogen or methyl, R2 and R3, together with each other and the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring system which may optionally contain one or more additional heteroatoms, and A is lower alkylene or aryl-lower alkylene, and nontoxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as inducers of the formation of interferon.
- -
-
-
